Author:
Yeung Aaron,Zagora Sophia L.,McCluskey Peter J.
Publisher
Springer International Publishing
Reference53 articles.
1. Akrout R, Fourati H, Mnif E, et al. Increased cardiovascular risk and premature atherosclerosis in rheumatoid arthritis. Ann Cardiol Angeiol (Paris). 2012;61:267–73.
2. Berger JR. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf. 2010;33:969–83.
3. Botsios C, Sfriso P, Ostuni PA, Todesco S, Punzi L. Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases. Rheumatology. 2007;46:1042–3.
4. Butler NJ, Lim LL, Giles TR, deSaint Sardos A, Ali A, Lee ST, Pasadhika S, Smith JR, Rosenbaum JT, Suhler EB. Rituximab in the treatment of refractory scleritis and non-infectious orbital inflammation: 24 week outcomes from a phase I/II prospective, randomized study. The association for research in vision and ophthalmology. Fort Lauderdale. 2011.
5. Campara M, Tzvetanov IG, Oberholzer J. Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation. Expert Opin Biol Ther. 2010;10:959–69.